Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Matthias Lauth

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5922-5384; OpenAlex author ID A5061882954. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 13

  1. Emerging concepts, hot topics, and open questions in today's pancreatic cancer research. Last author DOI 10.1016/j.bbcan.2026.189614↗
  2. The long non-coding RNA NEAT1 contributes to aberrant STAT3 signaling in pancreatic cancer and is regulated by a metalloprotease-disintegrin ADAM8/miR-181a-5p … Co-author DOI 10.1007/s13402-024-01001-0↗
  3. BAG6 restricts pancreatic cancer progression by suppressing the release of IL33-presenting extracellular vesicles and the activation of mast cells. Co-author DOI 10.1038/s41423-024-01195-1↗
  4. DYRK1B blockade promotes tumoricidal macrophage activity in pancreatic cancer. Last author DOI 10.1136/gutjnl-2023-331854↗
  5. IL-17A-producing CD8+ T cells promote PDAC via induction of inflammatory cancer-associated fibroblasts. Co-author DOI 10.1136/gutjnl-2022-327855↗
  6. A Quick Guide to CAF Subtypes in Pancreatic Cancer. Last author DOI 10.3390/cancers15092614↗
  7. The Immune Microenvironment in Pancreatic Cancer. Last author DOI 10.3390/ijms21197307↗
  8. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Co-author DOI 10.1136/gutjnl-2018-316451↗
  9. Genetic and pharmacologic abrogation of Snail1 inhibits acinar-to-ductal metaplasia in precursor lesions of pancreatic ductal adenocarcinoma and pancreatic inj… Co-author DOI 10.1038/s41388-017-0100-4↗
  10. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pan… Co-author DOI 10.1016/j.neo.2014.05.010↗
  11. The role of pancreatic and duodenal homeobox 1 as a therapeutic target in pancreatic cancer. First author DOI 10.1517/14728222.2014.945427↗
  12. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.08.002↗
  13. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Last author DOI 10.1158/0008-5472.can-10-4621↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anna I. Brichkina · 5 shared papers, 2023–2026 · strength 0.96
  2. Thomas Mathias Gress · 5 shared papers, 2019–2026 · strength 0.79
  3. Magdalena Huber · 4 shared papers, 2020–2026 · strength 0.69
  4. Malte Buchholz · 5 shared papers, 2019–2025 · strength 0.68
  5. Detlef Klaus Bartsch · 6 shared papers, 2013–2025 · strength 0.65
  6. Corinna Ulrike Keber · 3 shared papers, 2024–2026 · strength 0.60
  7. Jörg Walter Bartsch · 3 shared papers, 2020–2026 · strength 0.60
  8. Elke Pogge von Strandmann · 3 shared papers, 2020–2026 · strength 0.55
  9. Uta‐Maria Bauer · 2 shared papers, 2025–2026 · strength 0.49
  10. Christian Alexander Bauer · 3 shared papers, 2019–2023 · strength 0.33
  11. Carsten Denkert · 2 shared papers, 2024 · strength 0.31
  12. Felix S.R. Picard · 2 shared papers, 2023–2024 · strength 0.29
  13. Veronika Lutz · 2 shared papers, 2023–2024 · strength 0.29
  14. Bilal Alashkar Alhamwe · 2 shared papers, 2020–2024 · strength 0.26
  15. Volker Fendrich · 4 shared papers, 2013–2018 · strength 0.25
  16. Kimia Zandieh · 1 shared paper, 2025 · strength 0.20
  17. Yutong Gao · 1 shared paper, 2025 · strength 0.20
  18. Xiangdi Yu · 1 shared paper, 2025 · strength 0.20
  19. Pietro Di Fazio · 1 shared paper, 2025 · strength 0.20
  20. Emily P. Slater · 2 shared papers, 2018–2020 · strength 0.18
  21. Jens Waldmann · 3 shared papers, 2013–2018 · strength 0.16
  22. Viviane Ponath · 1 shared paper, 2024 · strength 0.15
  23. Shiv K. Singh · 1 shared paper, 2023 · strength 0.12
  24. Matthias M. Gaida · 1 shared paper, 2023 · strength 0.12
  25. Philipp Mayer · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.